Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Syndax Pharma (NQ: SNDX )

22.28 -0.90 (-3.88%)
Streaming Delayed Price Updated: 11:13 AM EDT, May 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Syndax Pharma

< Previous 1 2 3 Next >
Syndax Pharmaceuticals: Q4 Earnings Insights
Via Benzinga
Earnings Scheduled For February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
Earnings Preview: Syndax Pharmaceuticals
Via Benzinga
Is The Stock Market Ready To Plunge? The Warning Signs Are Here...
Find out how to spot the exhaustion of demand and the bearish analogue you could refer to to anticipate the down move. 
Via Talk Markets
What's Going On With Leukemia-Focused Syndax Pharmaceuticals Stock Today?
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) shares are trading higher after the company shared data from multiple trials of revumenib in combination with standard-of-care agents in patients with... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
What's Going On With Syndax Pharmaceuticals Stock Monday?
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) announced topline data from the AUGMENT-101 trial of revumenib in adult and pediatric patients with relapsed/refractory (R/R) KMT2A-rearranged (KMT2Ar) acute... 
Via Benzinga
Earnings Scheduled For August 3, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million. 
Via Benzinga
Citigroup Maintains Buy Rating for Syndax Pharmaceuticals: Here's What You Need To Know
Via Benzinga
What 7 Analyst Ratings Have To Say About Syndax Pharmaceuticals
Via Benzinga
Earnings Scheduled For November 2, 2023
Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million. 
Via Benzinga
Earnings Outlook For Syndax Pharmaceuticals
Via Benzinga
Analyst Ratings for Syndax Pharmaceuticals
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2023
Via Benzinga
Why AERWINS Technologies Shares Are Trading Higher By Around 90%; Here Are 20 Stocks Moving Premarket
Gainers AERWINS Technologies Inc. (NASDAQ: AWIN) shares rose 90.2% to $0.2297 in pre-market trading. Aerwins Technologies is considering strategic alternatives for non-core operations including, not... 
Via Benzinga
Syndax Pharmaceuticals Earnings Preview
Via Benzinga
Expert Ratings for Syndax Pharmaceuticals
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 369 companies hit new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 112 companies set new 52-week lows. 
Via Benzinga
Vail Resorts, Carnival, Opera And Other Big Stocks Moving Lower On Friday
U.S. stocks traded higher, with the Nasdaq Composite gaining around 1% on Friday. Here are some big stocks recording losses in today’s session. Corcept Therapeutics Incorporated (NASDAQ: CORT) shares... 
Via Benzinga
Topics Stocks
Exposures US Equities
Stocks That Hit 52-Week Lows On Thursday
  During the session on Thursday, 461 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 169 companies set new 52-week lows. 
Via Benzinga
Syndax-Incyte Partnered Chronic Graft-Versus-Host Disease Achieves Primary Endpoint In Pivotal Trial, FDA Submission Planned By 2023 End
Syndax Pharmaceuticals (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) announced topline data from the AGAVE-201 trial of axatilimab, in adult and pediatric patients with chronic graft-versus-host... 
Via Benzinga
Syndax Pharmaceuticals Set for Potential Breakthrough with Revumenib: Analyst Calls It 'Potentially Best-In-Class' In Competitive Landscape
Guggenheim Partners initiated coverage on Syndax Pharmaceuticals Inc (NASDAQ: SNDX) with a BUY rating and a  
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  Monday's session saw 175 companies set new 52-week lows. 
Via Benzinga
Earnings Scheduled For May 8, 2023
Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 per share on revenue of $462.26 million. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2023
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.